CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Lonza to buy five US sites from Merck KGaA

By Reuters News

Nov 3 (Reuters) - Contract drug manufacturer Lonza LONN.S will more than double its US footprint after agreeing to buy five manufacturing sites in the country from Merck KGaA MRCG.DE, the Swiss company said on Tuesday.

The deal will bring the number of Lonza's US sites to nine, and expand its cell and gene therapy capabilities, while Germany's Merck continues its shift towards a concentrated life science portfolio.

  • The deal is valued in a range of low- to mid-triple-digit million Swiss francs, the companies said, and is expected to close in the middle of next year.

  • Around 1,100 employees are set to join Lonza's workforce under the transaction.

  • Barclays analysts described the deal as "strategically positive" for Lonza, pointing to upside from utilisation and margin improvement.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk